This page contains details of ongoing consultations where the opinion and input of BIA members is sought.
If you are commenting on any consultation as an individual or on behalf of another organisation such as RCPath and you belong to the BIA please do copy your form to BIA@Hartleytaylor.co.uk. Responders will receive a BIA Guideline Review Support Certificate which can be used to self-credit up to 10 CPD points for commenting on a consultation and we will incorporate your individual/other organisation response into the response of the BIA.
Consultation on BTS Bronchiectasis Quality Standards
The draft BTS Quality Standard for Bronchiectasis is now available for public consultation until 20 June 2022.
The draft statement can be found here.
Recruitment to the NICE advisory committee for urinary tract infections (update) 2022 - CLOSING SOON
This is a polite reminder that this recruitment period is due to close in one week. We are looking for experts to join our quality standards advisory committee (QSAC) to develop the urinary tract infections (update). We need people with a professional or practitioner background in the topic in the following roles:
- Community pharmacist with experience in diagnosis and management of UTIs.
- Practice nurse or physician associate experienced in the assessment of people with UTIs.
Information on the posts is available on the NICE website, please follow this link for details:
The deadline for applications is Wednesday 25 May 2022 at 17.00.
What are NICE quality standards?
NICE quality standards are a concise set of prioritised statements designed to drive measurable quality improvements within a particular area of health or care.
If you have any queries please contact QualityStandards@nice.org.uk
NHSEI Policy testing: Amendments to policies on drugs for PrEP and Tenofovir Alafenamide for HIV 1
We would like to invite your feedback on amendments to two Clinical Commissioning Policies:
- 2112A - Reimbursement for the use of generic and second line drugs for Pre Exposure Prophylaxis (PrEP) for the prevention of HIV
- 2112B - Tenofovir alafenamide for treatment of HIV 1 in adults and adolescents
As a key stakeholder, we would like to hear your views on the changes to these policies before they are considered further by NHSEI.
[2112A] Reimbursement for the use of generic and second line drugs for Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV
What are the changes?
The evidence for tenofovir alafenamide (TAF) and emtricitabine (see 2112B) has been added to the policy, alongside the inclusion criteria for use. It is proposed to be an alternative for a sub selection of patients for whom other options are not suitable or appropriate.
- [2112A] Draft policy update_Reimbursement for generic and second line drugs for PrEP.pdf
- [2112A] Equality and Health Inequalities Assessment_Reimbursement for drugs for PrEP.pdf
- [2112A] Stakeholder Response Form_Reimbursement for drugs for PrEP.docx
The main changes can be seen on pages 3 and 4 of the draft and can be compared against the current version of the policy.
[2112B] Tenofovir alafenamide for treatment of HIV-1 in adults and adolescents
What are the changes?
Tenofovir alafenamide (TAF) (in combination with emtricitabine) has been identified as an alternative in pre-exposure prophylaxis (PrEP) and added to the PrEP policy (see 2112A). The inclusion criteria has been amended and simplified.
- [2112B] Draft policy update_Tenofovir Alafenamide (TAF) for HIV 1.pdf
- [2112B] Equality and Health Inequalities Assessment_TAF for HIV.pdf
- [2112B] Stakeholder Response Form_TAF for HIV 1.docx
The main changes can be seen on pages 5 and 6 of the draft and compared against the current version of the policy.
What is NHSEI asking you to do?
Please review the changes to one or both of the policies and give your feedback to the questions in the corresponding stakeholder testing response forms above. Please use a separate form for each policy. You are welcome to respond on behalf of a group or organisation you are involved with, or as an individual. You may want to consult others as part of your response, or you can forward this email to other stakeholders.
The stakeholder testing is open for 14 days and the last day for feedback is 26 May 2022. Please return your completed stakeholder response forms to email@example.com. In order for your response to be processed we can only consider responses that are submitted using the attached stakeholder response forms. Please use the unique reference number "2112" in the subject line of your email so that your response reaches the appropriate mailbox.
Healthcare professional survey - pharma communications strategies
Do you want to influence how you communicate with Pharma?
This survey is around pharma’s relationship with doctors and what they feel is appropriate / optimal in terms of content / channel of communication. The idea is to raise awareness in the pharmaceutical industry of how doctors want to be communicated with. The results of the survey will be published in the pharmaceutical press (pharmaphorum) as well as circulated through industry contacts. This is an opportunity for doctors to have a say in the way that they communicate with the pharma industry and should hopefully help to stimulate meaningful debate at a time where the relationship is somewhat strained.
Recently Published Consultations
NICE guideline: Cellulitis and erysipelas: antimicrobial prescribing Published Sept 2019
NICE guideline: Lyme disease Consultation closed 12/03/2019
NICE guideline: Lyme disease. Published April 2018
NICE guideline: otitis media (acute): antimicrobial prescribing. Published March 2018
NICE guidance: Cystic Fibrosis - Diagnosis and management. Published October 2017
UK SMI V 28: investigation of cytomegalovirus infection Consultation closed 27/12/2018
NICE draft guideline: Surgical site infections: prevention and treatment (update) Consultation closed 18/12/2018
NICE guideline CG191 Pneumonia in adults: diagnosis and management. Consultation closed 26/09/18
NICE draft guideline on acute cough: antimicrobial prescribing. Consultation closed 17/09/18
NICE consultation on proposed changes to the technology appraisals programme - phase 2. Consultation closed 01/03/18
UK NSC consultation on chlamydia screening in pregnancy. Consultation closed 22/02/18
BHIVA Standards of Care for People Living with HIV 2018. Consultation closed 20/02/18
BHIVA guidelines for the management of HIV infection in pregnant women 2018. Consultation closed 19/02/18
BHIVA guidelines for the management of TB/HIV co-infection in adults. Consultation closed 09/02/18
NICE guideline on hip, knee and shoulder replacement. Consultation closed 05/02/18
UK SMI B 29: Investigation of specimens for screening for MRSA. Consultation closed 02/02/18
Use of organs from Hepatitis C viraemic donors in Hepatitis C negative recipients. Consultation closed 02/02/18
NICE QS on cystic fibrosis. Consultation closed 19 January 2018. Expected publication: 18 May 2018
Topic engagement exercise: NICE emergency and acute medical care QS. Consultation closed 01/12/17. Click for BIA comments.
UK NSC consultation: guidance on the development, production and review of information to support screening. Consultation closed 16/11/17. We hope to publish responses and an updated version of the guidance within 12 weeks of the conclusion of the consultation.
NICE QS Consultation: HIV testing - encouraging uptake. Published September 2017.
NICE QS Consultation: Physical health of people in prison. Published September 2017.
UK NSC consultation: antenatal screening for human t-cell lymphotrophic virus (HTLV). Review completed Dec 2017
PHE UK guidelines for the management of contacts of invasive Group A Streptococcus infection in community settings. Consultation closed 02/10/17
British Society for Rheumatology draft guidelines: Biological DMARD safety guidelines in inflammatory arthritis. Consultation closed 04/09/17.
NICE guidance on emergency and acute medical care in over 16s: service delivery and organisation. Consultation closed 14/08/17. Expected publication date: 20/12/17. Click for BIA comments submitted
NICE guideline on sore throat (acute): antimicrobial prescribing. Consultation closed 14/08/17. Expected publication date tbc. Click for BIA comments submitted
Stakeholder consultation: High Consequence Infectious Diseases Interim Paediatric. Consultation closed 19/07/17.
NICE draft guideline: Flu vaccination - increasing uptake. Expected publication date: 10/01/2018.
Click for BIA comments on this consultation
NICE Surveillance Reports - Healthcare associated infections: prevention and control in primary and community care. Survey closed 27/06/17.
UK SMI V 04 - Investigation of hepatitis B infection. Published June 2017
NICE draft guideline on sinusitis (acute): antimicrobial prescribing. Published October 2017
NICE draft guideline on cystic fibrosis: diagnosis and management. Published 25 October 2017. Click for BIA comments.
UK National Screening Committee consultation: screening for Group B Streptococcus in pregnancy. Review completed March 2017
NICE Quality Standard Topic Engagement Exercise: HIV testing: encouraging uptake. Published Sept 2017
NICE guideline on Managing Common Infections. Consultation closed 28/11/16. Expected publication date tbc.
NICE Quality Standard Consultation: Vaccine uptake in under 19's. Published March 2017
NICE Diagnostics Consultation Document: Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay). Published Jan 2017
NICE Consultation on Abbreviated Technology Appraisal (ATA) Process. Consultation closed 24/08/16. Comments are currently being reviewed and an updated version is due to be presented to the NICE board in November 2016.
NICE Guideline: Sickle cell disease: managing acute painful episodes in hospital - Surveillance consultation. Consultation closed 02/06/16. Anticipated review decision publication: August 2016
UK SMI V 37: Chlamydia trachomatis infection - testing by Nucleic Acid Amplification Tests (NAAT). Published May 2018, updated Jan 2017
NICE draft guideline consultation: Multimorbidity: clinical assessment and management. Guideline published September 2016.